Thus, established IGF-1R inhibitors in combination with Notch inhibitors that showed clinical activity against ACC (e.g., the pan-Notch inhibitor crenigacestat or the γ-secretase inhibitor AL101) can be a suitable option for future clinical trials with advanced/recurrent ACC[30]. Here, IGF1R is linked to adrenal cortex carcinoma.